Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarechale Cap. Regulatory News (MAC)

Share Price Information for Marechale Cap. (MAC)

Share Price is delayed by 15 minutes
Get Live Data
7.60    1.05 (16.03%)
Bid:
7.20
Ask:
8.00
Spread: 0.80 (11.111%)
Market Cap: £9.08m
MAC Live PriceLast checked at - London Stock Exchange

Intraday Marechale Cap. Share Chart

Final Results

15 Aug 2012 16:00

RNS Number : 1105K
Marechale Capital PLC
15 August 2012
Β 

ο»Ώ

15 August 2012

Β 

Marechale Capital plc

("Marechale Capital" of the "Company")

Β 

Consolidated Financial Statements for the year ended 31 March 2012

Β 

Chairman's Statement

For the year ended 31 March 2012

Β 

During the financial year ending March 2012, Marechale Capital has continued to build on its position as an investment banking and corporate finance business specialising in advising and raising capital for high growth UK companies. Revenue from advisory fees and commissions increased by 10% from Β£632k to Β£694k, despite losing Β£50k of non-recurring rental income last year, which generated an Operating Profit of Β£25k compared to an Operating Loss in 2011 of Β£58k.

Β 

The Board is highly encouraged by this performance which was well above plan and despite difficult market conditions.

Β 

During the year the Company has been active in marketing its services and has engaged and completed thirteen transactions of which six generated, in addition to the usual cash fees, equity, equity options and warrants.

Β 

Marechale Capital's focus is on advising growth companies and funds, mainly private but also quoted, with a particular expertise in the renewable, consumer and leisure sectors; the latter, in particular, has become an area in which the Company is developing a leading reputation. The Company's two key areas of activity are Growth Capital through private equity transactions, for more established businesses, and Development Capital, fundraising for smaller growth companies, the latter typically being Enterprise Investment Scheme (EIS) qualifying.

Β 

The Company completed two Growth Capital private equity transactions during the year; advising and procuring Β£38m of funding to help the management team of Halcyon Hotels plc on the buy-back of seven hotels from the administrators of Von Essen, and Osprey Publishing Ltd on their refinancing and subsequent Β£4m investment by Alcuin Partners Ltd. During the current year, Marechale Capital has also completed its second publishing company transaction.

Β 

The second area of activity is Development Capital fundraising, typically Β£1-2m, for established but earlier stage growth companies which are usually EIS qualifying, where a range of investors known to the Company can benefit from the tax advantages under EIS. We have successfully completed funding for a number of such businesses during the year, including an online Gaming business called Betclearer, as well as further fundraisings for existing successful clients including pubs group Heartstone Inns, anaerobic digestion business Future Biogas, and the online trading exchange, Traccr.

Β 

Marechale Capital generates revenues from advisory fees and fund raising commissions, as well as equity, warrants or a percentage of the 'carry' on fund raisings. The three year plan is to increase the profitability of the business and increase the asset value of the Company through increasing and realising value in these equity, warrant and carry positions. For reasons of uncertainty and illiquidity, we are unable reliably to estimate a value for the warrants, but nonetheless we have been able to start to demonstrate the rationale in this by selling one such warrant position, for a four times uplift in strike price value in March realising a gain of Β£17,000.

Β 

When requested, Marechale Capital will invest its own funds in support of its clients fundraisings, and to this end, on 1 April 2011, the Company issued 5m new shares at 2p/share, representing an increase of approximately 10% raising Β£100,000.

Β 

Marechale Capital is quoted on the AIM Market of the London Stock Exchange and, whilst it has received and looked at a number of potentially interesting acquisitions, investment, and merger opportunities particularly in fund management, and remains open to such approaches, none to date has been progressed.

Β 

Market conditions remain challenging, as they have been for a number of years, and whilst there is increased demand for Marechale Capital's advisory and fund raising services, investor appetite is restrained, even with EIS tax advantages, and only available for exceptional investment opportunities, particularly in the Development Capital division. The Government has however further enhanced the EIS scheme in this year's budget, and the Board believes that this will assist in securing funding for quality qualifying companies seeking funding in the future.

Β 

Marechale Capital has a good pipeline of Growth and Development Capital transactions in its core sectors of renewables, consumer, and leisure. However, we continue to remain cautious about overall market conditions, which affect the operating environments of our client companies and the environment in which we assist them in raising their debt and equity funding.

Β 

Mark Warde-Norbury

Chairman

15 August 2012

Β 

Β 

For further information please contact:

Marechale Capital

Tel: +44 (0)20 7628 5582

Mark Warde-Norbury

Patrick Booth-Clibborn

Smith & Williamson Corporate Finance

Tel: +44 (0)20 7131 4000

Dr Azhic Basirov

David Jones

Β 

Consolidated Income Statement

Year ended 31 March 2012

Β 

Year ended

Year ended

31-Mar

31-Mar

Notes

2012

2011

(Β£)

(Β£)

Continuing operations

Revenue

2

694,403

631,909

Cost of sales

(47,110)

(53,837)

Gross profit

647,293

578,072

Administrative expenses

(621,779)

(636,169)

Operating profit/ (loss)

25,514

(58,097)

Investment revenues

1,175

2,220

Other (losses) and gains

(9,025)

29,596

Profit/ (loss) before tax

17,664

(26,281)

Taxation

0

0

Profit/ (Loss) for the year on continuing operations

17,664

(26,281)

Profit/ (Loss) per share

3

(Pence)

(Pence)

Basic

- Continuing operations

0.03

(0.06)

Β 

Consolidated Statement of Comprehensive Income

Β 

Year ended

Year ended

31-Mar

31-Mar

2012

2011

(Β£)

(Β£)

Profit/ (loss) for the year

17,664

(26,281)

Other comprehensive income

Revaluation of investments

(4,612)

(6,722)

Realised loss on investments

0

0

(4,612)

(6,722)

Total recognised comprehensive income

(all attributable to owners of the parent)

13,052

(33,003)

Β 

Β 

Consolidated Balance Sheet

Year ended 31 March 2012

Β 

Year ended

Year ended

31-Mar

31-Mar

2012

2011

(Β£)

(Β£)

Non current assets

Property, plant and equipment

0

0

Current assets

Available for sale investments

72,238

62,826

Trading investments

1,600

30,150

Trade and other receivables

152,092

82,481

Cash and cash equivalents

310,750

242,064

536,680

417,521

Total assets

536,680

417,521

Current liabilities

Trade and other payables

(54,630)

(48,523)

Total current liabilities

(54,630)

(48,523)

Net assets

482,050

368,998

Equity

Capital and reserves attributable to equity shareholders

Share capital

2,421,870

2,371,870

Share premium account

1,227,453

1,177,453

Revaluation reserves

16,989

21,601

Other reserves

(50,254)

(50,254)

Retained earnings

(3,134,008)

(3,151,672)

482,050

368,998

Β 

Β 

Statement of Changes in Equity

Year ended 31 March 2012

Β 

Share capital

Share premium

Revaluation reserve

Other reserves

Retained earnings

Group

(Β£)

(Β£)

(Β£)

(Β£)

(Β£)

Balance at 31st March 2010

2,371,870

1,177,453

28,323

(50,254)

(3,125,391)

Issue of ordinary share capital

0

0

0

0

0

Release of reserve for lapsed options

0

0

0

0

0

Transactions with owners

0

0

0

0

0

Total comprehensive income

Loss for the period

0

0

0

0

(26,281)

Revaluation during the period

0

0

(6,722)

0

0

Total comprehensive income

0

0

(6,722)

0

(26,281)

Balance at 31st March 2011

2,371,870

1,177,453

21,601

(50,254)

(3,151,672)

Issue of ordinary share capital

50,000

50,000

0

0

0

Release of reserve for lapsed options

0

0

0

0

0

Transactions with owners

50,000

50,000

0

0

0

Total comprehensive income

Profit for the period

0

0

0

0

17,664

Revaluation during the period

0

0

(4,612)

0

0

Total comprehensive income

0

0

(4,612)

0

17,664

Balance at 31st March 2012

2,421,870

1,227,453

16,989

(50,254)

(3,134,008)

Movements of the Revaluation reserve consist of:

2012

2011

Unrealised gains/ (losses)

(4,612)

13,360

Release of unrealised gains to Profit and Loss

0

(20,082)

(4,612)

(6,722)

Other reserves consist of:

Reserve for employee share ownership plan ('ESOP')

(50,254)

(50,254)

Reserve for share based payments

0

0

(50,254)

(50,254)

Β 

The Reserve for ESOP comprises 232,603 shares in the Group held in an ESOP Trust. As at 31st March 2012 and 2011, none of the shares had been unconditionally granted to any of the Group's employees and had an aggregate market value of Β£3,490 (2011: Β£4,652).

Β 

Β 

Consolidated Cash Flow Statement

Year ended 31 March 2012

Β 

Year ended

Year ended

31-Mar

31-Mar

2012

2011

(Β£)

(Β£)

Net cash from operating activities

Continuing operations: Operating profit/ (loss)

25,514

(58,097)

Operating cash flows before movements in working capital

25,514

(58,097)

Movement in working capital

(Increase) in receivables

(69,610)

(19,508)

Increase/ (decrease) in payables

6,107

(69,588)

(63,503)

(89,096)

Operating cash flow

(37,989)

(147,193)

Investment activities

Interest receivable

1,175

2,220

Proceeds on disposal of trading investments

19,525

0

Proceeds on disposal of available for sale investments

0

27,606

Expenditure on available for sale investments

(14,025)

(40,000)

Cash flow from investing activities

6,675

(10,174)

Financing

Issue of share capital

100,000

0

Cash flow from financing activities

100,000

0

Net increase/ (decrease) in cash and cash equivalents

68,686

(157,367)

Cash and cash equivalents at start of period

242,064

399,431

Cash and cash equivalents at end of period

310,750

242,064

Increase/ (decrease) in cash and cash equivalents

68,686

(157,367)

Β 

Β 

Notes to the Financial Information

Year ended 31 March 2012

Β 

1. Basis of preparation

The financial information contained in this announcement is based on the Company's financial statements which have been prepared in accordance with IFRS and International Financial Reporting Interpretations Committee ('IFRIC') interpretations adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS, with the prior periods being reported on the same basis. The financial statements have been prepared on the historical cost basis as modified by the valuation of certain financial instruments.

Β 

The principal accounting policies adopted in the preparation of the financial information in this announcement are set out in the Company's full financial statements for the year ended 31 March 2012.

Β 

2. Business and geographical segments

The directors consider that there is only one activity undertaken by the Group, that of corporate finance advisory. All of this activity was undertaken in the United Kingdom.

Β 

2012

2011

(Β£)

(Β£)

Continuing operations

Fees earned from corporate finance

694,403

631,909

Β 

3. Earnings per share

Earnings

Earnings

(Β£)

(Β£)

Based on a profit/ (loss) of

17,664

(26,281)

No.Β shares

No. shares

Weighted average number of Ordinary Shares in issue

52,437,410

47,437,410

for the purpose of basic earnings per share

Β 

4. Other Matters

The financial information for the year ended 31 March 2012 set out in this announcement does not constitute statutory financial statement, as defined in section 434 of the Companies Act 2006, but is based on the statutory financial statement for the year then ended. Those financial statements, upon which the auditors have issued an unqualified opinion, will be delivered to the Registrar of Companies.

Β 

Copies of the Company's full audited Annual Report and Financial Statements for the year ended 31 March 2012 will be sent to shareholders in due course and will be available on the Company's website: www.marechalecapital.com.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
FR PAMITMBABBPT
Date   Source Headline
9th Nov 20112:50 pmRNSHolding(s) in Company
22nd Sep 201111:20 amRNSResult of AGM
20th Sep 201110:03 amRNSDirector/PDMR Shareholding
25th Aug 20119:46 amRNSFinal Results
18th Apr 20111:44 pmRNSDirector/PDMR Shareholding
14th Apr 20112:16 pmRNSHolding(s) in Company
12th Apr 20117:00 amRNSDirectorate Change
31st Mar 20113:28 pmRNSIssue of Equity
29th Mar 20113:17 pmRNSDirectorate Appointment & Dealing
28th Mar 20113:39 pmRNSDirector/PDMR Shareholding
16th Mar 20119:20 amRNSDirector/PDMR Shareholding
25th Feb 20113:46 pmRNSHolding(s) in Company
9th Feb 20112:02 pmRNSDirector/PDMR Shareholding
19th Jan 20111:34 pmRNSDirector/PDMR Shareholding
13th Jan 20114:19 pmRNSHolding(s) in Company
11th Jan 201112:27 pmRNSDirector/PDMR Shareholding
15th Dec 201012:00 pmRNSHalf Yearly Report
29th Sep 20103:06 pmRNSResult of AGM
22nd Sep 201010:34 amRNSDirector/PDMR Shareholding
7th Sep 201012:00 pmRNSFinal Results and Notice of General Meeting
17th Mar 20109:00 amRNSChange of Adviser
22nd Feb 20103:15 pmRNSResult of GM
12th Feb 201012:00 pmRNSDirector/PDMR Shareholding
4th Feb 201011:00 amRNSDirector/PDMR Shareholding
29th Jan 201012:00 pmRNSNotice of General Meeting
12th Jan 20107:00 amRNSApplication for New Ordinary Shares
23rd Dec 20092:31 pmRNSHalf Yearly Report
17th Dec 20095:15 pmRNSResult of AGM
7th Dec 200912:28 pmRNSHoldings in Company / Directors Dealings
23rd Nov 20097:00 amRNSAcquisition and AGM
23rd Oct 20099:17 amRNSHolding in Company
15th Oct 20092:41 pmRNSChange of Name of Nominated Adviser and Broker
30th Sep 20094:00 pmRNSAnnual Report & Accounts
18th Sep 20097:00 amRNSNotifiable Interests
18th Sep 20097:00 amRNSHolding in Company
28th Aug 20092:30 pmRNSAcquisition of Whim Gully Capital LLP
28th Aug 20092:30 pmRNSPreliminary Results and Notice of General Meeting
21st Jul 20097:00 amRNSDisposal
6th Aug 200810:59 amRNSDirector/PDMR Shareholding
23rd Jun 20087:00 amRNSAppointment of joint broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.